Therapy with the potent, selective, potential first-in-class MAT2A inhibitor IDE397 induced responses in sufferers with regionally superior or metastatic urothelial most cancers or...
Francisco Hernandez-Ilizaliturri, MDAs lisocabtagene maraleucel (Breyanzi; liso-cel) lately joined the record of FDA-approved CAR T-cell therapies for the remedy of sufferers with relapsed...
